In a 65-year-old diabetic man with severe facial cellulitis/ulcer who is already receiving meropenem and amikacin adjusted for impaired renal function, and whose culture grows Staphylococcus aureus susceptible to gentamicin, levofloxacin, and clindamycin, should clindamycin be added to his regimen?

No, do not add clindamycin to meropenem and amikacin

You should simplify and de-escalate your antibiotic regimen now that you have culture results showing methicillin-susceptible S. aureus (MSSA). Meropenem already provides excellent coverage for MSSA, making the addition of clindamycin redundant and unnecessarily broad.

Why This Regimen Needs Adjustment

Your current triple-drug regimen (meropenem + amikacin + potential clindamycin) is excessive for a susceptible S. aureus infection:

• Meropenem alone covers MSSA effectively 1. It is FDA-approved for complicated skin and skin structure infections and provides robust activity against methicillin-susceptible staphylococci.

• Amikacin is unnecessary for MSSA. Aminoglycosides like amikacin and gentamicin are indicated for gram-negative coverage, particularly Pseudomonas aeruginosa and other resistant gram-negatives 2. Your culture shows S. aureus sensitive to gentamicin, levofloxacin, and clindamycin—this is clearly MSSA, not a gram-negative pathogen.

• Adding clindamycin creates triple coverage for a single susceptible organism, which increases toxicity risk (particularly nephrotoxicity with amikacin in a patient with renal impairment), promotes resistance, and provides no clinical benefit.

The Correct Approach: Targeted De-escalation

Switch to monotherapy with an anti-staphylococcal agent that matches your susceptibility results:

First-line options for severe facial cellulitis/ulcer with MSSA:

• Clindamycin 600 mg IV every 8 hours (adjust for renal function) 3, 4, 3, 4

  • Excellent MSSA coverage
  • Penetrates soft tissue and bone well
  • Inhibits bacterial toxin production (important in severe staphylococcal infections)
  • Oral formulation available for step-down therapy

• Cefazolin 1-2 g IV every 8 hours (adjust for renal function)

  • First-generation cephalosporin with excellent MSSA activity
  • Well-tolerated
  • Cost-effective

• Continue meropenem only if:

  • There is concern for polymicrobial infection (though your culture shows only S. aureus)
  • The patient is critically ill and you need broad coverage while awaiting final sensitivities
  • There are deep tissue concerns requiring anaerobic coverage

Why clindamycin is particularly appropriate here:

The IDSA guidelines specifically recommend clindamycin 600 mg IV/PO three times daily for hospitalized patients with complicated SSTI 3, 4, 3, 4. For diabetic foot infections—which share similar pathophysiology with your patient's facial ulcer—clindamycin is listed as an appropriate option for MSSA 5. The 2012 IDSA diabetic foot infection guidelines explicitly include clindamycin for moderate-to-severe infections in diabetic patients 5.

Critical Considerations for This Patient

Renal function adjustment is essential:

• You mention the patient has impaired renal function
• Stop amikacin immediately—aminoglycosides are nephrotoxic and ototoxic, particularly dangerous in renal impairment
• Adjust all antibiotics for creatinine clearance
• Meropenem requires dose reduction when CrCl ≤50 mL/min 1

Facial location matters:

• The face is a "difficult to drain" area per IDSA criteria, warranting antibiotic therapy 3, 4, 3
• Facial infections in diabetics carry higher morbidity risk
• Ensure adequate source control (debridement if needed)

Duration of therapy:

• IDSA recommends 7-14 days for complicated SSTI, individualized to clinical response 3, 4
• Transition to oral therapy (clindamycin 300-450 mg PO every 6-8 hours) once clinically improving

Common Pitfalls to Avoid

1. Continuing broad-spectrum therapy after culture results: This is the most common error. Meropenem + amikacin is appropriate for empiric coverage of severe infections with unknown pathogens or suspected resistant gram-negatives, but must be narrowed once susceptibilities return.

2. Ignoring aminoglycoside toxicity in renal impairment: Amikacin has no role in treating MSSA and poses significant nephrotoxic risk in your patient with existing renal dysfunction.

3. Assuming "more antibiotics = better outcome": Polypharmacy increases adverse effects, costs, and resistance without improving outcomes when a single targeted agent is sufficient.

4. Not checking for inducible clindamycin resistance: Before using clindamycin, ensure the lab performed a D-test if the isolate is erythromycin-resistant but clindamycin-susceptible, as this may indicate inducible resistance 4.

In summary: Stop amikacin, narrow from meropenem to clindamycin or cefazolin based on your susceptibility results, adjust all doses for renal function, and treat for 7-14 days with transition to oral therapy when appropriate.